Meeting
2016 ASCO Annual Meeting
Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).
Authors
Rachid C. Baz
Moffitt Cancer Center, Tampa, FL
Rachid C. Baz , Kenneth H. Shain , Melissa Alsina , Jason Brayer , Tami Rashal , Jennifer L Cooksey , Joel G Turner , Jana Dawson , Daniel Sullivan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02186834
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8013)
DOI
10.1200/JCO.2016.34.15_suppl.8013
Abstract #
8013
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2020 ASCO Virtual Scientific Program
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2020 ASCO Virtual Scientific Program
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
First Author: David H. Vesole